$PODD

BORIO LUCIANA sold $60K of PODD

BORIO LUCIANA sold 418 shares of INSULET CORP (PODD) at $143.27 on 2026-06-03.

Original reporting
SEC EDGAR · BORIO LUCIANA
Published Jun 4, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PODD
Neutral
medium confidence
Mentioned
$PODD
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PODDNeutralLow
01

Why it matters

The event updates insider ownership records but does not provide new company performance, guidance, or deal information.

02

Market read

Traders may monitor for follow-on insider selling or other catalysts, but this specific filing alone is unlikely to drive sustained repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; without broader insider activity, signal is limited.

Relevance 5/10Novelty 6/10Timing: Filed after-hours/late day (2026-06-04 16:23 ET) following the 2026-06-03 sale.

Background

This is an SEC Form 4 insider transaction disclosure (director selling shares).

Company-level read

Ticker impact

$PODDNeutralMedium confidence
Context

Insider Form 4 shows Insulet director Luciana Boro sold 418 shares in an open-market transaction on 2026-06-03.

Expected impact

Likely minimal; any reaction should fade quickly unless accompanied by other negative news.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan stated; however, the disclosed size (~$60K) is small relative to typical market cap and lacks new operating information.

Market effects

No clear read-through to medical device/insulin delivery peers from a single small insider sale.

None.

None.

Counterpoint

The absence of an identified 10b5-1 plan could be interpreted as discretionary selling, but the disclosed value is still modest.

Key entities

  • Insulet Corp

    Company whose director sold shares via an open-market transaction disclosed on Form 4.

  • BORIO LUCIANA

    Director who sold 418 shares at $143.27 on 2026-06-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.

$PODDMed

Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

Insulet PODD reports strong growth in Omnipod 5 AID system adoption, with Q2 2026 revenues up 23.8%. The company faces competition and macroeconomic pressures but has raised international growth guidance. PODD's earnings beat estimates for four straight quarters, with a 22.2% long-term growth rate. Management expects continued expansion and product development, including Omnipod 6 and a Type 2 system launch in 2027.

$PODDMed

Is Class Action Scrutiny Of Omnipod Controls Altering The Investment Case For Insulet (PODD)?

Insulet (PODD) faces class action lawsuits alleging false statements about manufacturing controls and safety risks in its insulin delivery products. The lawsuits, filed by Robbins Geller and Rosen Law Firm, cover shares bought between February 2025 and May 2026. Insulet maintains revenue growth guidance of 21-23% for 2026 despite recent recalls affecting 7 million units. Analysts project varying revenue and earnings estimates for 2029, with growth potential but increased risks due to manufacturi

$PODDMedAI 8/10

Insulet (PODD) Q2 2026 Earnings Call Transcript

Insulet (PODD) reported Q2 2026 revenue of $801.7M, up 22.7% constant currency and above guidance. Adjusted EPS was $1.66, up 41.5%. U.S. Omnipod revenue was $544.1M, and international was $251.8M. Management revised U.S. full-year Omnipod growth to 17% to 19% and raised international to 30% to 32%, citing weaker type 2 retention.